Deborah Telman - Gilead Sciences Gen Affairs
| GILD Stock | MXN 1,129 0.00 0.00% |
Insider
Deborah Telman is Gen Affairs of Gilead Sciences
| Age | 58 |
| Phone | 650 574 3000 |
| Web | https://www.gilead.com |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Barbara Schadler | Roche Holding AG | 61 | |
| Jitendra Tyagi | Bristol Myers Squibb | N/A | |
| Michael Hencke | Biogen Inc | N/A | |
| Susan Esq | Biogen Inc | 66 | |
| Jennifer Mauer | Merck Company | N/A | |
| Peter Griffith | Amgen Inc | 64 | |
| Thomas Schinecker | Roche Holding AG | 48 | |
| Natacha Gassenbach | Biogen Inc | N/A | |
| Johannes MD | Roche Holding AG | 66 | |
| Pascale Schmidt | Roche Holding AG | 50 | |
| Nancy Grygiel | Amgen Inc | 55 | |
| Alonzo Weems | Eli Lilly and | N/A | |
| Bruno Eschli | Roche Holding AG | N/A | |
| Timothy Power | Bristol Myers Squibb | N/A | |
| Peter Dannenbaum | Merck Company | N/A | |
| BCH BM | Bristol Myers Squibb | 57 | |
| Jacob Naarden | Eli Lilly and | 38 | |
| Caroline Litchfield | Merck Company | 54 | |
| Cristal Downing | Merck Company | 54 | |
| Michael CPA | Biogen Inc | 59 | |
| Anat Ashkenazi | Eli Lilly and | 51 | |
Management Performance
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel ODay, Chairman of the Board, CEO | ||
| Johanna Mercier, Chief Commercial Officer | ||
| Deborah Telman, Gen Affairs | ||
| Jyoti Mehra, Ex HR | ||
| Jacquie CFA, VP Relations | ||
| Diane Wilfong, Corp VP | ||
| Andrew Dickinson, Executive Vice President - Corporate Development and Strategy | ||
| Michael Quigley, VP Biology | ||
| Linda Higgins, VP Innovation |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 2.55 T | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Institutions | 84.16 % | |||
| Price To Earning | 282.94 X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 79.06 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gilead Stock Analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.